Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$4.07 USD
+0.19 (4.90%)
Updated Sep 19, 2024 09:36 AM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FATE 4.07 +0.19(4.90%)
Will FATE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FATE
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates
Other News for FATE
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Fate Therapeutics’ Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522
Fate Therapeutics (FATE) Gets a Hold from Stifel Nicolaus
Fate Therapeutics: Hold Rating Amidst Steady Q2 Financials and Clinical Progress
Wedbush Reaffirms Their Hold Rating on Fate Therapeutics (FATE)